Arrowstreet Capital, Limited Partnership Arcus Biosciences, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $3.21 Million - $5.08 Million	-122,773 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $1.03 Million - $1.96 Million	-60,616 Reduced 33.05%	122,773 $3.19 Million
Q3 2020 Nov 12, 2020	BUY	$17.14 - $25.47 $1.8 Million - $2.67 Million	104,860 Added 133.53%	183,389 $3.14 Million
Q2 2020 Aug 12, 2020	BUY	$13.97 - $36.56 $1.1 Million - $2.87 Million	78,529 New	78,529 $1.94 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.